Cargando…

Association between Polygenic Risk Score and One-Year Outcomes Following As-Needed Aflibercept Therapy for Exudative Age-Related Macular Degeneration

We investigated whether polygenic risk score (PRS) was associated with one-year outcome of as-needed aflibercept therapy for exudative age-related macular degeneration (AMD), including AMD (n = 129) and polypoidal choroidal vasculopathy (n = 132). A total of 261 patients were treated with as-needed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shijo, Taiyo, Sakurada, Yoichi, Yoneyama, Seigo, Kikushima, Wataru, Sugiyama, Atsushi, Matsubara, Mio, Fukuda, Yoshiko, Mabuchi, Fumihiko, Kashiwagi, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559528/ https://www.ncbi.nlm.nih.gov/pubmed/32962278 http://dx.doi.org/10.3390/ph13090257

Ejemplares similares

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Characteristics of intermediate age-related macular degeneration with hyperreflective foci
por: Kikushima, Wataru, et al.
Publicado: (2022)

Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Yoneyama, Seigo, et al.
Publicado: (2020)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration
por: Kikushima, Wataru, et al.
Publicado: (2017)

Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration
por: Fukuda, Yoshiko, et al.
Publicado: (2019)

Pachydrusen in Fellow Eyes Predict Response to Aflibercept Monotherapy in Patients with Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2020)

Comparison of two-year outcomes after photodynamic therapy with ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2017)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Distinct characteristics of central serous chorioretinopathy according to gender
por: Yoneyama, Seigo, et al.
Publicado: (2022)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Incidence and risk of advanced age-related macular degeneration in eyes with drusenoid pigment epithelial detachment
por: Shijo, Taiyo, et al.
Publicado: (2022)

Comparison of the 1-Year Visual and Anatomical Outcomes between Subthreshold Red (670 nm) and Yellow (577 nm) Micro-Pulse Laser Treatment for Diabetic Macular Edema
por: Kikushima, Wataru, et al.
Publicado: (2021)

Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration
por: Sakurada, Yoichi, et al.
Publicado: (2016)

Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results
por: Matsubara, Mio, et al.
Publicado: (2020)

Drusenoid Pigment Epithelial Detachment: Genetic and Clinical Characteristics
por: Shijo, Taiyo, et al.
Publicado: (2021)

Cuticular drusen presenting with central serous chorioretinopathy in both eyes: A case report
por: Hosoda, Shuhei, et al.
Publicado: (2022)

Ziv-aflibercept and bevacizumab for exudative age-related macular degeneration: A retrospective comparison of clinical outcomes and cost at 1 year
por: Singh, Sumit Randhir, et al.
Publicado: (2020)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Characteristics of Grape Shelf Eye Injuries at Vineyards in Japan
por: Kikushima, Wataru, et al.
Publicado: (2022)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in a COVID-19 patient: A case report
por: Kogure, Chio, et al.
Publicado: (2021)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Intravitreal sirolimus with adjunct aflibercept versus aflibercept monotherapy for persistent, exudative age-related macular degeneration: a pilot study
por: Rowe, Lucas W., et al.
Publicado: (2023)

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2017)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

One-year outcomes of fixed treatment of intravitreal aflibercept for exudative age-related macular degeneration and the factor of visual prognosis
por: Ono, Aoi, et al.
Publicado: (2018)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Genetic Risk Factors for Glaucoma and Exfoliation Syndrome Identified by Genome-wide Association Studies
por: Sakurada, Yoichi, et al.
Publicado: (2018)

Lysyl oxidase-like 1 gene polymorphisms in Japanese patients with primary open angle glaucoma and exfoliation syndrome
por: Mabuchi, Fumihiko, et al.
Publicado: (2008)

Lack of association between p53 gene polymorphisms and primary open angle glaucoma in the Japanese population
por: Mabuchi, Fumihiko, et al.
Publicado: (2009)

Additive effects of genetic variants associated with intraocular pressure in primary open-angle glaucoma
por: Mabuchi, Fumihiko, et al.
Publicado: (2017)

Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
por: Wykoff, Charles C, et al.
Publicado: (2014)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

Genetic variants associated with glaucomatous visual field loss in primary open-angle glaucoma
por: Mabuchi, Fumihiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_us5itrs1djc5pi0iutvmm43t6u